ClinicalTrials.Veeva

Menu
C

California Neuroscience Research Medical Group | Sherman Oaks, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Gantenerumab
LY3002813
Troriluzole
Donanemab
Desvenlafaxine Succinate
Varenicline
SR57746A
BMS-986446
Xaliproden
Rimegepant

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 16 total trials

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptom...

Enrolling
Alzheimer's Disease
Mental Disorders
Drug: Placebo
Drug: Donanemab

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatmen...

Active, not recruiting
Migraine
Drug: Placebo comparator dosing
Drug: Rimegepant 75mg every other day dosing

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants...

Enrolling
Alzheimer Disease, Early Onset
Other: Placebo
Drug: BMS-986446

Trial sponsors

Pfizer logo
Roche logo
Biohaven logo
Lilly logo
Bristol-Myers Squibb (BMS) logo
Sanofi logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems